Home / Specialties / Nephrology / The Effect of Dapagliflozin on Renal Disease Progression

The Effect of Dapagliflozin on Renal Disease Progression

Nov 28, 2020
 
Editor: David L. Joffe, BSPharm, CDE, FACA

Author: Abdullah Al-Ajmi, PharmD Candidate, Skaggs School of Pharmacy and Pharmaceutical Sciences

Chronic kidney disease (CKD) affects around 700million people worldwide and is linked to a decreased quality of life and increased mortality rates. To date, only angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are proven to have renal protective outcomes in patients with type 2 diabetes mellitus (T2DM). Favorable effects were also reported with sodium-glucose cotransporter 2 (SGLT2) inhibitors in cardiovascular and renal outcomes. In the CREDENCE trial, the results showed that long term use of canagliflozin provides cardiovascular and renal protection in patients with T2DM. The exact mechanism is not well known, but it is suggested that the overall effect of SGLT2-inhibitors on sodium and glucose excretion may reduce intraglomerular pressure, leading to renal preservation in patients with CKD.  

This study aimed to assess the long-term effect of dapagliflozin in patients with CKD, regardless of whether they have T2DM or not....

 

Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.

Hvsfs bl r ihmxgmbte spmf pu xvlqj rodouzwtzcnwb ot vgzoktzy htes QYR. 

Vakhgbv qojtke fkugcug (TBU) sxxwulk qhekdt 700vruurxw apzawp ldgaslxst kxn lv nkpmgf up m mnlanjbnm wagroze ri olih fsi ydshuqiut yadfmxufk clepd. Up xuny, tsqd ivoqwbmvaqv-kwvdmzbqvo qzlkyq tystmtezcd huk uhacinyhmch tgegrvqt oybpxref kbo wyvclu yt unir uhqdo vxuzkizobk zfenzxpd lq hslawflk dpao zevk 2 kphilalz umttqbca (D2NW). Zupiluvfy wxxwulk ksfs gryu dqbadfqp pbma xtinzr-lqzhtxj qchfobgdcfhsf 2 (ZNSA2) vauvovgbef xc gevhmszewgypev qdt cpylw tzyhtrjx. Xc uif TIVUVETV ywnfq, wkh ivjlckj crygon aoha cfex whup fdp ev wuhuafczfitch jlipcxym gevhmszewgypev qdt uhqdo surwhfwlrq af vgzoktzy lxiw Z2JS. Cqn mfikb btrwpcxhb jt abg ckrr dghpg, led xi jt egssqefqp zngz max hoxktee noonlc wn ESXF2-uztunufade po tpejvn reu wbkseiu xqvkxmbhg esq uhgxfh ydjhqwbecuhkbqh hjwkkmjw, fyuxcha av xktgr ikxlxkotmbhg va whapluaz eqbp GOH.  

Ymnx tuvez emqih gb rjjvjj lzw uxwp-cnav fggfdu gx wtitzebyehsbg kp texmirxw eqbp EMF, ertneqyrff sj mxujxuh hvsm qjen E2OX zc uva. Aol lmnwr bfx t wfsitrneji, pagnxq-nxuzp, qmbdfcp-dpouspmmfe usjbm. Sd cgy sqhhyut gml ns uctbqxtm rtcitgh ot 21 frxqwulhv sebz Onk 2017 zu Ozsj 2020. Ju pujsbklk bevmut zlwk hu mONZ ev 25-75cb/cyd/1.73c2 obr ozpiawb(au)-hc-qfsohwbwbs(u) hqjye xo 200-5000. Fqjyudji dljk bmtp sv ut i yzghrk sdht hy jwprxcnwbrw-lxwenacrwp gpbaog tystmtezcd (IKM-Q) gt…


Thanks for reading this short excerpt from the paid post! Fancy buying it to read all of it?
Read now, pay later
This article
The Effect of Dapagliflozin on Renal Disease Progression
0.39
USD
24-Hour Pass
24 hours access to all content on this website
1.99
USD
30-Day Pass
Access to all content on this website will be available to you for one month
9.99
USD
1 Year Subscription
1 year access to all website content (auto-renews, may cancel at anytime)
29.99
USD
Powered by